Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics 2022. CA Cancer J Clin. 2022;72:7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• de Mel S, Lim SH, Tung ML, et al. Implications of heterogeneity in multiple myeloma. Biomed Res Int. 2014;2014:232546. doi:10.1155/2014/232546
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management [published correction appears in Am J Hematol 2020; Nov;95(11): 1444]. Am J Hematol. 2020;95:548–567. doi:10.1002/ajh.25791
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Hillengass J, et al. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. J Natl Compr Canc Netw. 2019;17:1154–1165. doi:10.6004/jnccn.2019.0049
   PubMed Web of Science ®Google Scholar
• Guillerey C, Nakamura K, Vuckovic S, et al. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci. 2016;73:1569–1589. doi:10.1007/s00018-016-2135-z
   PubMed Web of Science ®Google Scholar
• Swamydas M, Murphy EV, Ignatz-Hoover JJ, et al. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J Hematol Oncol. 2022;15:17. doi:10.1186/s13045-022-01234-2
   PubMed Web of Science ®Google Scholar
• Kastritis E, Zagouri F, Symeonidis A, et al. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia. 2014;28:2075–2079. doi:10.1038/leu.2014.110
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Duggan P, Neri P, et al. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Leuk Lymphoma. 2018;59:1920–1926. doi:10.1080/10428194.2017.1403026
   PubMed Web of Science ®Google Scholar
• Dávila J, González-Calle V, Escalante F, et al. Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival. Br J Haematol. 2022;198:278–287. doi:10.1111/bjh.18182
   PubMed Web of Science ®Google Scholar
• Hájek R, Sandecka V, Špička I, et al. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. Br J Haematol. 2020;190:189–197. doi:10.1111/bjh.16572
   PubMed Web of Science ®Google Scholar
• Landgren O, Hofmann JN, McShane CM, et al. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. JAMA Oncol. 2019;5:1293–1301. doi:10.1001/jamaoncol.2019.1568
   PubMed Web of Science ®Google Scholar
• Gao W, Li J, Jian Y, et al. Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation. Int J Hematol. 2019;109:169–174. doi:10.1007/s12185-018-2547-7
   PubMed Web of Science ®Google Scholar
• Chahin M, Branham Z, Fox A, et al. Clinical Considerations for Immunoparesis in Multiple Myeloma. Cancers (Basel). 2022;14:2278. doi:10.3390/cancers14092278
   PubMed Web of Science ®Google Scholar
• González-Calle V, Cerdá S, Labrador J, et al. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica. 2017;102:922–931. doi:10.3324/haematol.2016.158345
   PubMed Web of Science ®Google Scholar
• Ozaki S, Harada T, Yagi H, et al. Polyclonal immunoglobulin recovery after autologous stem cell transplantation is an independent prognostic factor for survival outcome in patients with multiple myeloma. Cancers (Basel). 2020;12:12. doi:10.3390/cancers12010012
   Web of Science ®Google Scholar
• Eisfeld C, Ebeling E, Wullenkord R, et al. Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma. Ann Hematol. 2020;99:1907–1915. doi:10.1007/s00277-020-04068-5
   PubMed Web of Science ®Google Scholar
• Lei A, Liao X, Zhu P, et al. The significance of autologous hematopoietic stem cell transplantation on immunoglobulin reconstitution and prognosis in elderly patients with multiple myeloma. Hematology. 2023;28(1):2255800. doi:10.1080/16078454.2023.2255800
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548. doi:10.1016/S1470-2045(14)70442-5
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–2962. doi:10.1182/blood-2016-01-631200
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346. doi:10.1016/S1470-2045(16)30206-6
   PubMed Web of Science ®Google Scholar
• Sørrig R, Klausen TW, Salomo M, et al. Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. PLoS One. 2017;12(12):e0188988. doi:10.1371/journal.pone.0188988
   PubMed Web of Science ®Google Scholar
• Geng C, Yang G, Wang H, et al. Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients. Leuk Lymphoma. 2021;62(4):883–890. doi:10.1080/10428194.2020.1855345
   PubMed Web of Science ®Google Scholar
• Gao W, Li J, Wu Y, et al. Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation. Ann Hematol. 2019;98:1177–1184. doi:10.1007/s00277-018-3574-4
   PubMed Web of Science ®Google Scholar
• Ravi P, Kumar S, Gonsalves W, et al. Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer J. 2017;7(6):e569. doi:10.1038/bcj.2017.46
   PubMedGoogle Scholar
• Huang W, Wei X, Wei Q, et al. Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma. Transl Cancer Res. 2021;10(12):5258–5266. doi:10.21037/tcr-21-1627
   PubMed Web of Science ®Google Scholar
• Garcia de Veas Silva JL, Cejudo MT G, Garcia Perojil Jimenez A, et al. HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients. Front Oncol. 2021;11:599532), doi:10.3389/fonc.2021.599532
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086–1107. doi:10.1002/ajh.26590
   PubMed Web of Science ®Google Scholar
• Lakhwani S, Rosiñol L, Puig N, et al. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection. Haematologica. 2023. Published online November 30, 2023. doi:10.3324/haematol.2023.284154
   PubMedGoogle Scholar
• Kubicki T, Dytfeld D, Wróbel T, et al. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial. Br J Haematol. 2023;203(5):792–802. https://doi.org/10.1111/bjh.19097.
   PubMed Web of Science ®Google Scholar